197 related articles for article (PubMed ID: 33020065)
1. Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD
Zhu J; Lu J; Tung HC; Liu K; Li J; Grant DM; Xie W; Ma X
Drug Metab Dispos; 2020 Dec; 48(12):1372-1379. PubMed ID: 33020065
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.
Wang P; Shehu AI; Lu J; Joshi RH; Venkataramanan R; Sugamori KS; Grant DM; Zhong XB; Ma X
Biochem Pharmacol; 2017 Dec; 145():218-225. PubMed ID: 28888949
[TBL] [Abstract][Full Text] [Related]
3. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.
Bing C; Xiaomeia C; Jinhenga L
Drug Metabol Drug Interact; 2011; 26(3):113-8. PubMed ID: 21980963
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.
Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
Antimicrob Agents Chemother; 2015 Nov; 59(11):6791-9. PubMed ID: 26282412
[TBL] [Abstract][Full Text] [Related]
5. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.
Chen B; Li JH; Xu YM; Wang J; Cao XM
Clin Chim Acta; 2006 Mar; 365(1-2):104-8. PubMed ID: 16182272
[TBL] [Abstract][Full Text] [Related]
6. A simplified method for detecting isoniazid compliance in patients receiving antituberculosis chemotherapy.
Hashiguchi M; Ohno K; Sakuma A; Hino F; Tanaka T; Ohtsuji M; Matsumoto N; Yanase K; Urae A; Hosogai Y; Sato N; Yazaki A; Matsuda K; Yamazaki K; Rikihisa T
J Clin Pharmacol; 2002 Feb; 42(2):151-6. PubMed ID: 11831537
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites.
Khan SR; Morgan AG; Michail K; Srivastava N; Whittal RM; Aljuhani N; Siraki AG
Biochem Pharmacol; 2016 Apr; 106():46-55. PubMed ID: 26867495
[TBL] [Abstract][Full Text] [Related]
8. Regulation of intracellular levels of NAD: a novel role for CD38.
Aksoy P; White TA; Thompson M; Chini EN
Biochem Biophys Res Commun; 2006 Jul; 345(4):1386-92. PubMed ID: 16730329
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.
Chen B; Shi HQ; Feng MR; Wang XH; Cao XM; Cai WM
Front Pharmacol; 2022; 13():932686. PubMed ID: 35928262
[No Abstract] [Full Text] [Related]
10. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid metabolism and hepatotoxicity.
Wang P; Pradhan K; Zhong XB; Ma X
Acta Pharm Sin B; 2016 Sep; 6(5):384-392. PubMed ID: 27709007
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid: metabolic aspects and toxicological correlates.
Preziosi P
Curr Drug Metab; 2007 Dec; 8(8):839-51. PubMed ID: 18220565
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Amlabu V; Mulligan C; Jele N; Evans A; Gray D; Zar HJ; McIlleron H; Smith P
Int J Tuberc Lung Dis; 2014 May; 18(5):528-30. PubMed ID: 24903787
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid Acetylation Phenotyping in the Japanese: The Molar Metabolic Ratio INH/AcINH.
Kohno H; Kubo H; Takada A; Mori M; Arias TD
Am J Ther; 1996 Jan; 3(1):74-78. PubMed ID: 11856999
[TBL] [Abstract][Full Text] [Related]
15. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
16. Eosinophil peroxidase oxidizes isoniazid to form the active metabolite against M. tuberculosis, isoniazid-NAD
Babu D; Morgan AG; Reiz B; Whittal RM; Almas S; Lacy P; Siraki AG
Chem Biol Interact; 2019 May; 305():48-53. PubMed ID: 30922765
[TBL] [Abstract][Full Text] [Related]
17. A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver.
Li F; Wang P; Liu K; Tarrago MG; Lu J; Chini EN; Ma X
Drug Metab Dispos; 2016 Nov; 44(11):1742-1751. PubMed ID: 27531952
[TBL] [Abstract][Full Text] [Related]
18. Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction.
Ng KY; Zhou H; Zhang YL; Hybertson B; Randolph T; Christians U
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 847(2):188-98. PubMed ID: 17070115
[TBL] [Abstract][Full Text] [Related]
19. A validated liquid chromatography-tandem mass spectrometry assay for the analysis of isoniazid and its metabolite acetyl-isoniazid in urine.
Maputla SP; Van Dalen W; Joubert A; Norman J; Castel S; van der Merwe M; Wiesner L
J Mass Spectrom Adv Clin Lab; 2024 Apr; 32():11-17. PubMed ID: 38356778
[TBL] [Abstract][Full Text] [Related]
20. Role of CYP3A in isoniazid metabolism in vivo.
Liu K; Li F; Lu J; Gao Z; Klaassen CD; Ma X
Drug Metab Pharmacokinet; 2014; 29(2):219-22. PubMed ID: 24172716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
